De Novo Ventures, of Menlo Park, Calif., added Kenneth Pereira as chief financial officer.

Dendreon Corp., of Seattle, added Robert Hershberg as vice president of strategic product development.

EntreMed Inc., of Rockville, Md., appointed Udo Klein vice president of research and development.

EraGen Biosciences, of Madison, Wis., named Kiu Leung vice president, quality and manufacturing.

Genaissance Pharmaceuticals Inc., of New Haven, Conn., appointed Karen Dawes to its board.

Genentech Inc., of South San Francisco, promoted Diane Parks to senior vice president and general manager, specialty therapeutics and managed care. It also promoted Vishva Dixit to vice president, research - molecular oncology.

Incyte Corp., of Wilmington, Del., appointed David Hastings executive vice president and chief financial officer.

Inflazyme Pharmaceuticals Ltd., of Vancouver, British Columbia, named Gregorio Aversa vice president, research; Andre Beaulieu general counsel; and Janice Mallison vice president, clinical and regulatory affairs.

Inpharmatica Ltd., of London, appointed Andrew Ayscough director of chemistry and added seven medicinal chemists.

Integrity Pharmaceutical Corp., of Indianapolis, added Blake Paterson as chief operating officer.

IntraBiotics Pharmaceuticals Inc., of Palo Alto, Calif., elected Mark Perry to its board.

Islet Technology Inc., of St. Paul, Minn., added Joseph Lahti and Gary Griffin to its board. Lahti will serve as chairman and Griffin will serve as the company's chief financial officer.

Kos Pharmaceuticals Inc., of Miami, added Andrew Koven as senior vice president, general counsel and Ralf Rosskamp as senior vice president, research and development.

Medicure Inc., of Winnipeg, Manitoba, appointed Moray Merchant vice president, market development.

Metabasis Therapeutics Inc., of San Diego, added Scott Hecker as executive director of chemistry.

Nastech Pharmaceutical Co. Inc., of Bothell, Wash., added Paul Johnson as senior vice president, research and development and chief scientific officer.

Nautilus Biotech, of Evry, France, appointed Reinhard Koenig vice president, clinical and regulatory affairs of Nautilus Biotech USA.

PPD Inc., of Wilmington, N.C., appointed Gail McIntyre senior vice president, research for PPD Discovery.

Predix Pharmaceuticals Inc., of Woburn, Mass., elected Julian Adams and Ted Love to its board.

Repligen Corp., of Waltham, Mass., elected Thomas Ryan to its board.

Rigel Pharmaceuticals Inc., of South San Francisco, appointed Robin Cooper senior vice president of pharmaceutical sciences.

Senomyx Inc., of La Jolla, Calif., added John Poyhonen as vice president and chief business officer.

SoloHill Engineering Inc., of Ann Arbor, Mich., elected Timothy Solomon as president and chief operating officer.

Sunesis Pharmaceuticals Inc., of South San Francisco, elected Reynold Spector to its scientific advisory board.

United Therapeutics Corp., of Silver Spring, Md., named Stuart Rich chief medical officer, effective Jan. 1.